ABSTRACT
Biliary tract cancers (BTCs) are a heterogeneous group of neoplasms characterized by a dismal prognosis. At variance with most solid tumors, no effective molecular targeted agent has been currently approved for BTCs treatment and their molecular landscape has only been recently investigated. Comprehensive mutational profiling studies identified IDH1/2 and BAP1 as characteristic of intrahepatic cholangiocarcinomas, while extrahepatic cholangiocarcinomas and gallbladder carcinomas were characterized by frequent KRAS and TP53 alterations. Moreover, targeted next-generation sequencing has uncovered alterations in several key cellular pathways. BTC-specific alterations include disorders of major regulators of cell cycle and chromatin remodeling processes, as well as deregulation of the mTOR-, TGFbeta/Smad-and receptor tyrosine kinases signaling. The next step will be the correlation of these findings with clinical trials to identify predictive biomarkers for the development of personalized therapies. This will permit early access for BTC patients to innovative drugs.
INTRODUCTION
Biliary tract cancers (BTCs) are a heterogeneous group of cancers, representing only about 3% of all gastrointestinal malignancies (1). They may arise from the gallbladder (i.e. gallbladder carcinomas; GBC) or the biliary tree. These latter can The mortality rate for these neoplasms is increasing worldwide (4). Surgery represents the only curative option at early stages of the disease, which is, however, affected by a high rate of tumor recurrence (5).
Remarkably, early diagnosis has been demonstrated to increase the survival rate of only 5% (6), and by the clinical point of view, a definite diagnosis of cholangiocarcinoma can be significantly delayed also in advanced stages because of the wide range of alternative diagnoses, including benign biliary tree strictures (i.e. choledocholithiasis and iatrogenic bile duct injuries), primary sclerosing cholangitis and other primary and metastatic carcinomas (7).
At variance with most solid tumors, no effective molecular targeted agent has been approved for BTCs, and consequently BTC patients have limited access to innovative clinical trials. It has to be underlined that the most important issue hampering the introduction of new therapeutic options for BTCs' patients is represented by the limited information available on their molecular background ( Similar to what observed in the hepatitisassociated multistep liver carcinogenesis (9), several studies pinpointed a key role of inflammation-related cytokines on the induction of the malignant transformation of cholangiocytes. Among the others, interleukin 6 (IL-6) and its associated pathways have been demonstrated to be an important proinflammatory signaling in the biliary tree chronic inflammatory setting (10). Increased levels of IL-6 have been demonstrated in serum from cholangiocarcinoma (CCA) patients (10). Moreover, IL-6 levels significantly correlated with tumor burden and were significantly decreased two weeks after therapeutic surgery. Of note, IL-6 levels were able to discriminate between CCA and benign biliary disease with a sensitivity and specificity of 71% and 90%, respectively (11).
IL-6 has an autocrine role on CCA cell survival. Through the activation of the p38 and p44/p42 MAPK signaling (12), IL-6 promotes telomerase activity (13), up-regulation of Mcl-1 (14), and induces STAT3 activation (15). Notably, STAT3 expression is significantly up-regulated in dedifferentiated CCAs, and is associated with shorter survival of CCA patients (16).
Another important player in the promotion of malignant transformation of cholangiocytes is COX-2.
Cholestasis and the presence of oxysterols, oxidized forms of cholesterol, can significantly induce the overexpression of COX-2, which subsequently promotes cell growth (17). Moreover, inflammatory cytokines significantly up-regulate the inducible nitric oxide synthase (iNOS); iNOS directly binds to COX-2 and enhances COX-2 activity (18). It has been demonstrated a significant overexpression of both iNOS and COX-2 in reactive biliary epithelia and biliary intraepithelial neoplastic lesions (19 
CELL SURVIVAL PATHWAYS ACTIVATION
mTOR signaling is one of the most involved pathway in the maintenance of cell survival and inhibition of apoptosis in solid tumors. Aberrant expressions of activated forms of mTOR (phospho-mTOR) and of its downstream effectors (ph-AKT1, ph-p70S6K and/ or ph-4EBP1) is a common finding in BTCs (21, 22). Moreover, the overexpression of ph-mTOR has been associated to well-to-moderately differentiated tumors, and to tumors without metastatic spread (21). Elevated activated mTOR levels have been also associated to a significantly shorter overall survival for BTCs' patients (23).
Another important mTOR-related gene is the phosphatase and tensin homologue (PTEN) which is a key tumor suppressor frequently altered in BTCs. Low PTEN expression and decreased PTEN/ph-AKT1 and PTEN/ph-mTOR expression ratios are poor prognostic factors in ECCs (24).
The role of PIK3CA alterations in BTCs is still under study. In a Chinese series, 32% of CCAs showed a mutation in the PIK3CA gene (25); another study found only one mutated case out of 11 (26).
Our group recently further supported mTOR pathway relevance in BTCs by demonstrating a significant up-regulation of ph-mTOR and of its downstream effectors in 51% of a large series of BTCs (22). This altered activation could be partly explained by the concomitant presence of a mutation in one of the genes involved in the mTOR pathway (i.e., AKT, FBXW7, PIK3CA, PIK3C2A, PIK3C2G, PTEN).
TYROSINE KINASES RECEPTORS
The ErbB family of class I receptor tyrosine kinases comprises four distinct receptors: ErbB1 (EGFR), ErbB2 (HER2), ErbB3 and ErbB4 (27, 28). Somatic mutations in the tyrosine kinase domain of EGFR have been described in a subgroup of patients with either cholangiocarcinoma or gallbladder carcinoma (37, 38) . However, the clinical impact of these mutations should be further investigated. More recently, a whole-exome sequencing study identified recurrent mutations in the ErbB signaling (including EGFR,
ERBB2, ERBB3, ERBB4 and their downstream genes) in GBCs (39).
It is well known that c-Met plays an important role in carcinogenesis in many cancer types, including hepatic tumors (34, 40). Terada et al. reported a significant c-Met overexpression in 81% of proliferative lesions associated to choledocolithiasis (41) . Of note, c-Met was also significantly overexpressed in 58% of ICCs and correlated with tumor differentiation (41) .
Also defects in the TGF-beta signaling play a significant role in many malignancies, including BTCs. Transforming growth factor signaling pathway disturbance in biliary cancers results from intragenic mutations in either the TGF-beta type I and II receptor genes, or the TGF-beta gene itself (42, 43) . Moreover, homozygous or heterozygous deletions of the TGF-beta type I receptor gene has also been reported in biliary carcinomas (42, 43) . Of note, deregulation of the TGFbeta signaling is associated to an increased production of peritumoral fibrosis (44) , which is a hallmark of extrahepatic BTCs. In fact most EECs are often accompanied by abundant fibrous stroma (5).
Members of the FGFR family (i.e. FGFR1-4)
have been associated with mutations, amplifications and translocation events with oncogenic potential (45 
INTRACELLULAR SIGNALING
Several studies associated KRAS gene alterations to GBCs. However, the reported frequency of gene mutations (in codons 12, 13, and 61) varies from 0% to 80% (22, 48). Of interest, in Western countries, where GBC is most related to chronic cholecystitis and cholelithiasis, KRAS mutations are rarely encountered (0-10%). In contrast, in Japanese series, where GBCs may often be associated with a congenital abnormality, the frequency of KRAS mutations is markedly higher.
Activation of the KRAS oncogenes has been described also for other BTCs (49). The variable incidence of KRAS mutations reflects the anatomical location and the type of duct on which CCAs develop. In fact, KRAS mutations are more frequently observed in ECCs and ICCs of the periductal-spreading type, whereas are almost absent in the ICCs mass-forming type (50, 51 (56) . Of interest, the liver-specific targeted simultaneous disruption of SMAD4 and PTEN tumor suppressors generated a mouse model that develops biliary malignancies (57).
CELL CYCLE CHECKPOINT
The p16/cyclin D1/Rb pathway is one of the most important cell-cycle regulator in many different types of cancers (58) . Evidence for a role in biliary tract carcinogenesis derives from the demonstration of frequent cyclin D1 overexpression and inactivation of CDKN2A (p16) by a variety of mechanisms, including mutation, deletion, and abnormal hypermethylation (59). Ishikawa et al. reported a significant reduction of p16 expression due to promoter methylation in intraductal papillary neoplasms of livers with hepatolithiasis; intraductal papillary neoplasms are identified as precursor lesions of ICC (60) . Methylation of the CDKN2A promoter and homozygous deletion of the gene has also been frequently observed in ICCs (61, 62) .
Several studies pinpointed a central role for TP53 gene alterations in BTCs (63) . Also MDM2 gene amplification has been demonstrated as an important TP53 master deregulator in CCAs (64) . In our monoinstitutional series of 153 CCAs, the presence of TP53 mutations was the only significant independent prognostic factor (22). It has to be noted that although TP53 mutations are frequent in ICCs, their prevalence is significantly higher in ECCs and GBCs. In fact, somatic mutations of TP53 occur in almost half of GBCs (65).
METABOLIC RELATED FACTORS
Somatic mutations in the cytoplasmic and peroxisomal isocitrate dehydrogenase gene IDH1 and its mitochondrial counterpart IDH2 have been identified through large genomic screenings of human tumors (66) . These mutations cause a single amino acid change at a conserved arginine residue within the isocitrate binding site of IDH1 (R132) or IDH2 (R172, R140) resulting in decreased enzymatic activity for oxidative decarboxylation of isocitrate to alfa-ketoglutarate (67) .
A seminal study on the mutational profiling of 287 gastrointestinal cancers identified IDH1 mutations in a significant subset of patients affected by ICC (68) . In the same study it was shown that the prevalenceof IDH1 and IDH2 gene mutations was greater than the combined prevalence of activating mutations in AKT1, KRAS, NRAS, and BRAF in ICC, making it the most prevalent drug targetable gene alteration in this cancer type (68) . This finding was further supported by deep sequencing studies, which identified IDH1 and IDH2 gene mutations in almost 20% of ICCs (22, 65, 68).
The presence of IDH1/2 mutations in a significant proportion of ICCs may offer novel insights on how to develop targeted approaches against this treatment-refractory disease. The physiological IDH1/2 function is the catalyzation of the oxidative carboxylation of isocitrate to alpha-ketoglutarate. IDH1/2 mutations confer neomorphic activity through the reduction of alphaketoglutarate to the metabolite R(-)-2-hydroxyglutarate (2HG), resulting in the accumulation of 2HG in tumor tissues (67, 69) . A recent study suggests that circulating 2HG may serve as a surrogate biomarker of IDH1 or IDH2 mutation status in ICC, and its levels are related to tumor burden (70).
CHROMATIN REMODELING GENES
Genome-wide sequencing has identified frequent mutations in chromatin remodeling genes across different tumor types. These discoveries have profound implications in understanding the mechanistic basis of epigenetic changes that have recently been demonstrated as widespread in most tumors (71) .
The seminal report of Jiao et al. highlighted the key role of mutations in chromatin-remodeling genes in ICC with frequent inactivating mutations in three different genes (ARID1A, BAP1, PBRM1) affecting almost half of the tumors sequenced. These studies point to chromatin remodeling as a crucial area of investigation for innovative therapeutic strategies. Moreover, comparison of somatic mutation data for cholangiocarcinoma and gallbladder carcinoma suggests that, while both tumor types arise from biliary epithelium, they are genetically distinct (65).
Mutations in PBRM1 (which encodes BAF180) were identified in 41% of renal cell carcinomas, making PBRM1 the second most frequently mutated gene in these cancers after VHL (72) . BAF180 contains six tandem bromodomains that bind acetylated histones, two bromo-adjacent homology (BAH) domains that mediate protein-protein interactions and a high-mobility group (HMG) domain that binds nucleosomal DNA. Given the function of these domains, BAF180 may recruit © 1996-2016 PBAF complexes to specific loci (73) . BAF180 binds preferentially to different acetylated lysine configurations of histone tails, indicating that it may contribute to the recognition of the histone code (74) . The frequency of mutations of this gene in CCAs was attested at between 5 and 20% depending on histopathological subtype (Table 1) , further underlying its importance in human cancers (22, 39, 65, 75) .
The ARID1A subunit of SWI/SNF complexes was also recently found to be specifically mutated in primary human cancers. The ARID1A subunit contains an ARID domain that binds DNA in a sequence-nonspecific manner (76) . However, the role of this domain during the engagement and repositioning of a nucleosome is still not fully understood as PBRM1, ARID1A mutation frequencies significantly differ among CCA subtypes. Most ICC and ECC studies reported a mutation frequency of 5-20% (22, 65, 75) . In GBCs, ARID1A seems to be infrequently altered (22, 39).
Protein ubiquitination was initially seen as a mechanism to label proteins for degradation; however, this idea has evolved as we have come to understand that ubiquitination and deubiquitinating enzymes (DUBs) regulate various cellular processes, including DNA repair, gene transcription, cell membrane trafficking, cell cycle progression, stress response, cell communication, differentiation and apoptosis, and they also have a role in cancer (77) . BAP1 was discovered in a yeast twohybrid screen owing to its interaction with the RING finger domain of the tumor suppressor BRCA1. BRCA1 forms a heterodimer through its RING domain with BRCA1-associated RING domain 1 (BARD1), and this BRCA1-BARD1 tumor suppressor complex has E3 ubiquitin ligase activity that regulates the DNA damage response (DDR) (78) . BAP1 binds and deubiquitylates BARD1, thus modulating the E3 ligase activity of BRCA1-BARD1 (79). Mutations in the BAP1 gene seem to be specific of ICC tumors. Over 20% of ICC cases showed mutation in BAP1 in exome sequencing studies (20, 39, 65) . Differently studies performed on ECCs and GBCs showed no or low mutation frequency in BAP1 gene (20, 22, 39, 75).
CONCLUSIONS
BTCs are characterized by an unpredictable clinical behaviour. A significantly poorer prognosis is usually observed for ECCs and GBCs in comparison to mass-forming ICCs; however, significant clinical differences are observed also among tumors characterized by similar clinico-pathological features. As such, no biomarker prognostically stratify BTCs' patients, so far. However, the remarkable progress in molecular biology has led to a better understanding of the complex molecular landscape of BTCs'. Of note, particular mutational profiles have been identified according to tumor location through targeted next generation sequencing. Mutations in IDH1/2 and BAP1 have been recognized as characteristic of ICCs, while ECCs and GBCs are characterized by frequent KRAS and TP53 alterations. Alterations of the TP53 gene have also been associated with a worse patient prognosis.
Several other key cellular pathways, including disorders of major regulators of cell cycle and chromatin remodeling processes, as well as deregulation of the mTOR-, TGF-beta/Smad-and receptor tyrosine kinases signaling, have recently been shown to be altered in these tumors. This emerging knowledge is of utmost importance for cancer research and may be the breakthrough to novel innovative, targeted therapies.
The next step will be the correlation of these findings with clinical trials to identify predictive biomarkers for the development of personalized tailored therapies. This will also permit early access for BTCs patients to innovative drugs. 
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